Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Hai Zhang

Market Cap

6.01 Billion CNY

Sector

Healthcare

Website

https://www.gz-sanli.com

Description

GuiZhou SanLi Pharmaceutical Co.

Read More

Overview

Value

10

Growth

76

Health

61

Management

85

Analyst Opinion

80

Total

62

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Has a low level of debt
  • Low risk of bankruptcy
  • Has strong financial health
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Price-to-earnings ratio of 40.3 is higher than the market average (19.6x)
  • Very safe dividend

Market Peers

603439.SS

Key Figures

PE Ratio (TTM)

40.25

Margin Of Safety (DCF)

-46.51%

Revenue Growth (5 Year Average)

19.13%

Ratings Consensus

Buy

Share Buybacks

-3.77%

Dividend Yeild (TTM)

0.12%

Valuation

Value Score

10

  • Estimated intrinsic-value of 7.99 CNY is lower than current price ( 14.66 CNY)
  • Price-to-earnings ratio of 40.3 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 1.66% is worse than the market average (4.7%)
  • Margin-of-safety of -46.51% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 4.8 CNY

Current Price: 14.9 CNY

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

40.25x

Free Cashflow Yeild

1.66%

PE/Earnings Growth

0.74

Price/Book

5.36x

Growth

Growth Score

76

  • 5 Year Average Revenue growth of 19.13% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 19.42% is higher than the market average (14.48%)
  • 5 Year Average Cashflow growth of 24.87% is higher than the market average (12.35%)
  • Free Cashflow growth has improved this year
  • Earnings growth has slowed this year

Revenue Growth

19.13%

Earnings Growth

19.42%

Cashflow Growth

24.87%

Health

Health Score

61

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

9.54

Piostroski Score

4.00

Debt/Equity

0.19x

Current Assets/Liabilities

3.05x

Free Cashflow/Total Debt

0.64x

Debt/Capital

0.18x

Dividend

Secure Dividend Score

91

  • Very safe
  • Long term dividend payout ratio of 34.72% is considered good
  • Payout ratio (TTM) of 4.97% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Dividend growth has been accelerating recently
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.12% is less than the market average (1.85%)

Dividend Yeild

0.12%

Dividend Growth

40.65%

Payout Ratio (Earnings)

4.97%

Payout Ratio (Cashflow)

7.18%

Management

Management Score

85

  • Has issued new shares to finance growth when share price is high
  • Has returned higher dividends when earnings have risen
  • Return-on-capital-employed of 11.95% is higher than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of 14.70% is lower than the market average (15%)

Average Buybacks/Dilution

-3.77%

Recent Buybacks/Dilution

-0.42%

5 Year Price Volitility

36.42%

Return On Assets

10.79%

Return On Capital Employed

11.95%

Return On Equity

14.70%

Return On Free Cashflow

1314.17%

Return On Investments

127.30%

Analysts

Analyst Opinion

80

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

GuiZhou SanLi Pharmaceutical Co.,Ltd

Currency

CNY

Beta

0.966266

Vol Avg

22304265

Ceo

Hai Zhang

Cik

Cusip

Exchange

Shanghai

Full Time Employees

1007

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2020-04-28

Address

Xiayun Industrial Park

City

Guiyang

State

Country

CN

Zip

561100

Phone

86 851 3811 3572

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies